IRVINE, CA, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has signed a joint venture agreement with a Canadian public company, NHS Industries, Ltd. NHS Industries (CSE: (NHS), (OTC: NNHHF)). The group will focus on job creation, deliver and develop public and private access educational content, and research various delivery platforms for medical cannabinoid-related products and services, all based on the CBIS Economic Development Plan for Canada, (CBIS/CDN EDP).
The new Canadian-based partnership will expand Cannabis Science’s existing operations into Canada through its CDN EDP. CBIS will utilize its relationships with the Harvard International Phytomedicines and Medical Cannabis Institute (Harvard IPI) https://www.harvardipi.org as well as the Company’s collaborations with other leading institutions, to build and deliver educational content for the CDN EDP for the Canadian public.
The focus of the CDN EDP is to create jobs, research and educate the Canadian general public on the potential uses of medical cannabis to treat a variety of critical ailments and industrial uses. NHS Industries (CSE: (NHS), (OTC: NNHHF)) is a Canadian company listed on the Canadian Securities Exchange.
“Utilizing our relationships with the Harvard IPI – as well as with other leading treatment, research, and education institutions globally – puts us in a unique position to rapidly expand our operations and implement our world-class education, job creation, and research activities worldwide,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, CEO, and Co-Founder.
Beginning with launching targeted cash flow operations in the NHS Industries’ 50,000 sq. ft. greenhouse facility in Langley, BC., Cannabis Science will work with NHS Industries to find other suitable locations for different aspects of the CDN EDP operations including Richmond, North Vancouver, and downtown Vancouver, BC.
While the CBIS CDN EDP will initially focus on positive cash flow activities in the Canadian facility, the Company is now actively looking to add various industry partners to contract, merge, and expand the operations of the CDN EDP immediately. As well, the CDN EDP will launch entrepreneurial educational programs to offer a variety of educational programs directly related to the Company’s operations while continuing to move forward with its successful industrial and medical research of cannabis and hemp in Canada.
“We expect the CBIS CDN EDP research and educational programs will help develop specific skills among the workforce in the communities where we plan to operate and produce highly- skilled personnel for the jobs we hope to create directly and indirectly. This will contribute directly to the growth of our business in Canada,” concluded Mr. Dabney.
Cannabis Science has invested significantly in the Company’s pre-clinical research programs and experienced ground-breaking, promising results for the use of cannabinoids to treat a number of targeted indications. The Company has investigated varying doses of cannabinoids, and rigorously evaluated treatment outcomes and toxicity to generate data that will inform potential clinical trials.
Cannabis Science is currently conducting pre-clinical research on cannabinoid-based medicines to treat Lung Cancer, Pancreatic Cancer, Chronic Prostatitis, Obsessive Compulsive Disorder (OCD), Oro-bucco-lingual Dyskinesias, Oxidative Stress, Psychosis, and Post Traumatic Stress Disorder (PTSD), and other indications.
Cannabis Science has published two peer-reviewed research papers in the cancer research journal, Frontiers in Oncology:
Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids:
https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full
Enhancing the Therapeutic Efficacy of Cancer Treatment with Cannabinoids:
https://www.frontiersin.org/articles/10.3389/fonc.2018.00114/full
About Cannabis Science, Inc.
Cannabis Science is one of the first publicly-traded cannabinoid companies on the market, and is a leader in the research and development of cannabinoid-based medicines and associated delivery technologies. Cannabis Science and its research collaborators are currently conducting pre-clinical research on cannabinoid-based medicines with plans to transition to clinical trials on a number of products this year. Targeted indications include Lung Cancer, Pancreatic Cancer, Chronic Prostatitis, Obsessive Compulsive Disorder (OCD), Oro-bucco-lingual Dyskinesias, Oxidative Stress, Psychosis, and Post Traumatic Stress Disorder (PTSD). CBIS is also currently in negotiations to license the Company’s U.S. patent number 9,763,991 for the Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, including Sleep Disorders. CBIS recently announced its drug-development pipeline (www.cannabisscience.com) and the transition into clinical trials as well as other major company initiatives.
Cannabis Science takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, neurological conditions, and other indications as identified previously. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Cannabis Science, Inc. Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Contact Information
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832